What the FDA labels say about taking them together
Epinephrine and trastuzumab
Trastuzumab's FDA label of May 29, 2026 names epinephrine in its warnings and precautions section; the epinephrine labels PlainMeds reads (4) do not name trastuzumab. The trastuzumab label: “Interrupt Ogivri infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered.”
Check it at the source: the epinephrine FDA label on DailyMed (effective July 13, 2026, A-S Medication Solutions); the trastuzumab FDA label on DailyMed (effective May 29, 2026, Genentech, Inc.).
What does the epinephrine label say about trastuzumab?
Epinephrine's label (effective July 13, 2026) and its 3 other brand-application labels do not name trastuzumab in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Epinephrine), A-S Medication Solutions, effective July 13, 2026 (SPL set 6e811e28-0199-4df7-a916-5940c632401d), via openFDA; the full label on DailyMed
What does the trastuzumab label say about epinephrine?
Trastuzumab label, warnings and precautionsInterrupt Herceptin infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen).
Source: FDA drug label (Kanjinti, BLA761073), Amgen, Inc, effective June 23, 2026 (SPL set 9a94f5b2-b84e-4987-8ea1-c4346db5a5fa), via openFDA
Source: FDA drug label (Herzuma, BLA761091), Cephalon, Inc., effective December 22, 2025 (SPL set ae71c003-883a-4cd8-ad50-e8cc9a54e971), via openFDA
Source: FDA drug label (Ogivri, BLA761074), Mylan Institutional LLC, effective February 8, 2021 (SPL set 6b7938e6-14c7-4a65-9605-967542ecfb8f), via openFDA
Source: FDA drug label (Herceptin), Genentech, Inc., effective May 29, 2026 (SPL set 492dbdb2-077e-4064-bff3-372d6af0a7a2), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Epinephrine | Trastuzumab | |
|---|---|---|
| Labeled for | Asthma | Breast cancer |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $123.51 per unit 0.15 mg auto-injct | n/a |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once